Literature DB >> 32579023

Severe Hypoxemia in Early COVID-19 Pneumonia.

Pradeep Bhatia1, Sadik Mohammed1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32579023      PMCID: PMC7427389          DOI: 10.1164/rccm.202004-1313LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


× No keyword cloud information.
To the Editor: Luciano Gattinoni is widely acknowledged and respected for his work on acute respiratory distress syndrome, and this time he has suggested a very interesting concept describing the pathophysiology of the atypical presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–induced respiratory failure (1). Based on detailed observation of several cases, the hypothesis of dividing the time-related disease spectrum within two primary “phenotypes,” type L and type H, looks logical and might be helpful in the management of patients with coronavirus disease (COVID-19). The suggested cause of hypoxemia in type L is the loss of regulation of perfusion and loss of hypoxic vasoconstriction. Hypoxemia, leading to increased minute ventilation, primarily by increasing the Vt (up to 15–20 ml/kg), is associated with a more negative intrathoracic inspiratory pressure, and the magnitude of this pressure swing is projected as a factor that may determine the transition from the type L to the type H phenotype. However, the authors did not give an explanation for loss of regulation of perfusion and loss of hypoxic pulmonary vasoconstriction. We believe that diffuse pulmonary microvascular thrombosis is the cause of hypoxemia in early pneumonia by SARS-CoV-2. The histologic and immunohistochemistry studies suggest that in severe COVID-19 infection, a catastrophic, complement-mediated thrombotic microvascular injury occurs, with sustained activation of the actin pathway and lectin pathway cascades (2), leading to the recommendation of the use of early anticoagulation with low-molecular-weight heparin (3). We agree with the authors that to reverse hypoxemia, oxygenation by high-flow nasal cannula may be tried in patients with type L. However, we have reservations on the “early intubation and the use of PEEP [positive end-expiratory pressure] to prevent the transition to type H,” as the authors themselves have suggested that “the lung conditions are too good.” Effective oxygenation using high-flow nasal cannula/extracorporeal membrane oxygenation in type L should prevent pleural pressure swings and self-inflicted lung injury, leading to transition to type H. Additionally, some degree of “permissive hypoxemia” (4) may also be accepted in patients with type L to avoid ergotrauma, caused during ventilating the compliant lungs. However, other patients, who worsen to type H because of cytokine storm, as the authors have suggested, should be treated as severe acute respiratory distress syndrome, including higher positive end-expiratory pressure, if compatible with hemodynamics, prone positioning, and extracorporeal support.
  3 in total

Review 1.  Goal-directed therapy for severely hypoxic patients with acute respiratory distress syndrome: permissive hypoxemia.

Authors:  Mohamed Abdelsalam; Ira M Cheifetz
Journal:  Respir Care       Date:  2010-11       Impact factor: 2.258

2.  COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome.

Authors:  Luciano Gattinoni; Silvia Coppola; Massimo Cressoni; Mattia Busana; Sandra Rossi; Davide Chiumello
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

3.  Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.

Authors:  Cynthia Magro; J Justin Mulvey; David Berlin; Gerard Nuovo; Steven Salvatore; Joanna Harp; Amelia Baxter-Stoltzfus; Jeffrey Laurence
Journal:  Transl Res       Date:  2020-04-15       Impact factor: 7.012

  3 in total
  6 in total

1.  Possible silent hypoxemia in a COVID-19 patient: A case report.

Authors:  Munawar Gani; Aditya Rifqi Fauzi; Ririn Enggy Yuliyanti; Maria Patricia Inggriani; Bagus Nugroho; Denny Agustiningsih
Journal:  Ann Med Surg (Lond)       Date:  2020-11-24

Review 2.  Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms.

Authors:  Baohui Xu; Gang Li; Jia Guo; Toru Ikezoe; Karthikeshwar Kasirajan; Sihai Zhao; Ronald L Dalman
Journal:  J Vasc Surg       Date:  2021-02-15       Impact factor: 4.268

3.  COVID-19 with Rapid Progression to Hypoxemia Likely due to Imbalance between Ventilation and Blood Flow: A Case Report.

Authors:  Nobuyuki Koriyama; Akihiro Moriuchi; Kensaku Higashi; Tetsuro Kataoka; Takuro Arimizu; Go Takaguchi; Hideki Matsuoka; Maki Otsuka
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2022-02-04

4.  Causes of Hypoxemia in COVID-19.

Authors:  Zh A Donina
Journal:  J Evol Biochem Physiol       Date:  2022-03-05       Impact factor: 1.621

Review 5.  Persistent Lung Injury and Prothrombotic State in Long COVID.

Authors:  Mengqi Xiang; Haijiao Jing; Chengyue Wang; Valerie A Novakovic; Jialan Shi
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 6.  The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors.

Authors:  Mengqi Xiang; Xiaoming Wu; Haijiao Jing; Langjiao Liu; Chunxu Wang; Yufeng Wang; Valerie A Novakovic; Jialan Shi
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.